Registration - Amendment

AVANIR PHARMACEUTICALS for AVANIR PHARMACEUTICALS

Firm
Client
Income
—
Expenses
—

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.

LobbyistCovered position, as disclosed
CATHERINE DRATZ FERGUSON New —

Medical/Disease Research/Clinical Labs MED

Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.

LobbyistCovered position, as disclosed
CATHERINE DRATZ FERGUSON New —

Veterans VET

Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.

LobbyistCovered position, as disclosed
CATHERINE DRATZ FERGUSON New —

Medicare/Medicaid MMM

Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.

LobbyistCovered position, as disclosed
CATHERINE DRATZ FERGUSON New —

Budget/Appropriations BUD

Pharmaceutical Research and Development, Post-Acute Care Reform, Central Nervous System Disorders, Patent Reform, FDA Reform, FDA Approval Pathways, Medicare/Medicaid.

LobbyistCovered position, as disclosed
CATHERINE DRATZ FERGUSON New —

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
OTSUKA PHARMACEUTICAL CO., LTD. Japan Japan 100.0% —

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.